2017
Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction
NESTELBERGER, T., J. BOEDDINGHAUS, P. BADERTSCHER, R. TWERENBOLD, K. WILDI et. al.Základní údaje
Originální název
Effect of Definition on Incidence and Prognosis of Type 2 Myocardial Infarction
Autoři
NESTELBERGER, T., J. BOEDDINGHAUS, P. BADERTSCHER, R. TWERENBOLD, K. WILDI, D. BREITENBUCHER, Z. SABTI, C. PUELACHER, M.R. GIMENEZ, N. KOZHUHAROV, I. STREBEL, L. SAZGARY, D. SCHNEIDER, J. JANN, J. DU FAY DE LAVALLAZ, O. MIRO, F.J. MARTIN-SANCHEZ, B. MORAWIEC, D. KAWECKI, P. MUZYK, D.I. KELLER, N. GEIGY, S. OSSWALD, T. REICHLIN a C. MUELLER
Vydání
Journal of The American College of Cardiology, USA, Elsevier Science Inc. 2017, 0735-1097
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 16.834
Organizační jednotka
Lékařská fakulta
UT WoS
000410985400003
Klíčová slova anglicky
diagnosis; high-sensitivity cardiac troponin; type 2 myocardial infarction
Štítky
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 5. 12. 2017 13:14, Soňa Böhmová
Anotace
V originále
BACKGROUND Uncertainties regarding the most appropriate definition and treatment of type 2 myocardial infarction (T2MI) due to supply-demand mismatch have contributed to inconsistent adoption in clinical practice. OBJECTIVES This study sought a better understanding of the effect of the definition of T2MI on its incidence, treatment, and event-related mortality, thereby addressing an important unmet clinical need. METHODS The final diagnosis was adjudicated in patients presenting with symptoms suggestive of myocardial infarction by 2 independent cardiologists by 2 methods: 1 method required the presence of coronary artery disease, a common interpretation of the 2007 universal definition (T2MI(2007)); and 1 method did not require coronary artery disease, the 2012 universal definition (T2MI(2012)). RESULTS Overall, 4,015 consecutive patients were adjudicated. The incidence of T2MI based on the T2MI(2007) definition was 2.8% (n = 112). The application of the more liberal T2MI(2012) definition resulted in an increase of T2MI incidence of 6% (n = 240), a relative increase of 114% (128 reclassified patients, defined as T2MI(2012reclassified)). Among T2MI(2007), 6.3% of patients received coronary revascularization, 22% dual-antiplatelet therapy, and 71% high-dose statin therapy versus 0.8%, 1.6%, and 31% among T2MI(2012reclassified) patients, respectively (all p < 0.01). Cardiovascular mortality at 90 days was 0% among T2MI(2012reclassified), which was similar to patients with noncardiac causes of chest discomfort (0.2%), and lower than T2MI(2007) (3.6%) and type 1 myocardial infarction (T1MI) (4.8%) (T2MI(2012reclassified) vs. T2MI(2007) and T1MI: p = 0.03 and 0.01, respectively). CONCLUSIONS T2MI(2012reclassified) has a substantially lower event-related mortality rate compared with T2MI(2007) and T1MI. (Advantageous Predictors of Acute Coronary Syndromes Evaluation [APACE] Study; NCT00470587) (C) 2017 by the American College of Cardiology Foundation.